(Q35927476)

11 August 2017

1 reference

title

TRAIL and its receptors as targets for cancer therapy (English)

1 reference

11 August 2017

Mark J Smyth

4

0 references

Hideo Yagita

series ordinal

1

object named as

Hideo Yagita

1 reference

11 August 2017

Kazuyoshi Takeda

2

1 reference

PubMed ID

15504243

11 August 2017

Yoshihiro Hayakawa

series ordinal

3

1 reference

PubMed ID

15504243

11 August 2017

Ko Okumura

series ordinal

5

1 reference

11 August 2017

1 October 2004

1 reference

11 August 2017

1 reference

11 August 2017

95

1 reference

11 August 2017

777-783

1 reference

11 August 2017

10

1 reference

Identification and characterization of a new member of the TNF family that induces apoptosis

11 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

TRAIL and apoptosis induction by TNF-family death receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Tissue distribution of the death ligand TRAIL and its receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

How melanoma cells evade trail-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Isolation of human epidermal stem cells by adherence and the reconstruction of skin equivalents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Involvement of TRAIL/TRAIL-R interaction in IFN-alpha-induced apoptosis of Daudi B lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

TRAIL/Apo-2 ligand induces primary plasma cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02181.X

10.1111/J.1349-7006.2004.TB02181.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15504243